Sangamo Biosciences (SGMO) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Pentagon reportedly locked down, hazmat teams responding
Wedbush Recommends Buying Sangamo BioSciences (SGMO) on Weakness
August 6, 2015 1:07 PM EDTWedbush analyst Liana Moussatos is out defending Sangamo BioSciences (NASDAQ: SGMO) mid-day with shares getting sliced to the tune of 16% following Q2 results that missed the Street. The analyst notes the $218 million cash on hand is enough to cover significant clinical progress and they recommend buying the stock on weakness.
"We anticipate significant clinical progress in the next 6- 18 months," Moussatos... More
